A Common Practice of Widespread Antimicrobial Use in Horse Production Promotes Multi-Drug Resistance
A Common Practice of Widespread Antimicrobial Use in Horse Production Promotes Multi-Drug Resistance
复制标题
DOI：
10.1038/s41598-020-57479-9
复制
发表时间：
2020-01-22
影响因子：
4.6
通讯作者：
Cohen, N. D.
中科院分区：
文献类型：
--
作者：
Alvarez-Narvaez, S.;Berghaus, L. J.;Cohen, N. D.
将大环内酯类抗生素与利福平（MaR）预防性给药于经胸部超声检查发现肺部病变的明显健康的马驹（即，亚临床肺炎马驹）在美国很常见。这种做法在流行病学上与R.在这里，我们报告了用MaR治疗的马驹中的多药耐药性的直接证据。对用MaR（n=19）或麦芽酚酸镓（GaM; n=19）治疗的38匹亚临床肺炎马驹和19匹未治疗对照的粪便微生物组和耐药组进行了计算机模拟和体外分析。用MaR而不是GaM处理显著降低了粪便微生物群的丰度和多样性，并扩大了粪便中抗菌素耐药基因的丰度和多样性。实验感染马红球菌（Rhodococcus equi，R. equi），并用选择的MaR抗性R. equi，而对MaR敏感的R. Equi在GaM处理或未处理的地块中竞争抗性分离株。我们的研究结果表明，MaR的使用促进了R的多药耐药性。马和马的寄生虫，这些寄生虫会进入它们的环境，在那里它们可以持续存在并可能感染或定植马和其他动物。
The practice of prophylactic administration of a macrolide antimicrobial with rifampin (MaR) to apparently healthy foals with pulmonary lesions identified by thoracic ultrasonography (i.e., subclinically pneumonic foals) is common in the United States. The practice has been associated epidemiologically with emergence of R. equi resistant to MaR. Here, we report direct evidence of multi-drug resistance among foals treated with MaR. In silico and in vitro analysis of the fecal microbiome and resistome of 38 subclinically pneumonic foals treated with either MaR (n=19) or gallium maltolate (GaM; n=19) and 19 untreated controls was performed. Treatment with MaR, but not GaM, significantly decreased fecal microbiota abundance and diversity, and expanded the abundance and diversity of antimicrobial resistance genes in feces. Soil plots experimentally infected with Rhodococcus equi (R. equi) and treated with MaR selected for MaR-resistant R. equi, whereas MaR-susceptible R. equi out-competed resistant isolates in GaM-treated or untreated plots. Our results indicate that MaR use promotes multi-drug resistance in R. equi and commensals that are shed into their environment where they can persist and potentially infect or colonize horses and other animals.